A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma

• Status: Terminated
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seagen Inc.; Seattle Genetics, Inc.
• Treatments: Everolimus; Sirolimus

Criteria

Inclusion Criteria:

• Diagnosis of metastatic renal cell carcinoma with confirmed CD70 expression

• Previously treated with at least 1 tyrosine kinase inhibitor (TKI)

• Measurable disease

• Eastern Cooperative Oncology Group performance status 0 or 1

• Adequate lung and renal function

Exclusion Criteria:

• Prior treatment with anti-CD70-directed therapy

• Received more than one prior treatment with an mTOR inhibitor